ストックスクリーナーアプリを入手
1.69
2.87%
-0.05
前日終値:
$1.74
開ける：
$1.76
24時間の取引高:
82,191
Relative Volume:
0.35
時価総額：
$12.83M
収益：
当期純損益:
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
1週間 パフォーマンス:
-5.59%
1か月 パフォーマンス:
-20.28%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$1.55
$1.96
52週間の値動き範囲:
$1.485
$4.1599
Cerenome, Inc. Common Stock Stock (CNSY) Company Profile
Compare CNSY vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNSY
Cerenome, Inc. Common Stock
|
1.69 | 12.83M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.78 | 128.96B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
239.43 | 95.59B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.55 | 82.32B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
852.08 | 53.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.16 | 42.33B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cerenome, Inc. Common Stock Stock (CNSY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-03 | 開始されました | Lake Street | Buy |
| 2025-09-03 | アップグレード | D. Boral Capital | Hold → Buy |
| 2025-03-17 | 開始されました | D. Boral Capital | Buy |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-16 | 開始されました | Maxim Group | Buy |
Cerenome, Inc. Common Stock (CNSY) 最新ニュース
New Strong Sell Stocks for October 15th - Zacks Investment Research
Form 4 Cerenome, Inc For: 1 October By Investing.com - Investing.com Canada
Form 4 Cerenome, Inc For: 1 October - Investing.com India
Form 4 Cerenome, Inc For: 1 October By Investing.com - Investing.com UK
After stock grant vesting, Cerenome (CNSY) director Kyle Guse holds 1,843 shares directly. - Stock Titan
Three stock grants vest, giving Cerenome (CNSY)'s CFO 2,985 common shares. - Stock Titan
After acquiring 921 shares, Cerenome (CNSY) director holds 1,843 shares directly. - Stock Titan
Three stock grants vest as Cerenome (CNSY) CEO Hedrick acquires 6,387, 8,066 and 1,986 shares. - Stock Titan
A director acquires 921 shares as Cerenome (CNSY) stock grants vest, bringing direct holdings to 1,843. - Stock Titan
A stock grant vests at Cerenome (CNSY). Director Hawkins acquires 921 shares and holds 2,450 common shares. - Stock Titan
Form 4 Cerenome, Inc For: 1 October By Investing.com - Investing.com South Africa
Cerenome, Inc. (CNSY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cerenome, Inc. (CNSY) stock price, news, quote and history - Yahoo Finance UK
Cerenome plans to discuss billing and access for its spinal-fluid diagnostic platform. - Stock Titan
ServiceNow To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Cerenome forecasts its cash will last into 2028 with new financing - Stock Titan
Cerenome, Inc. announced that it expects to receive $20 million in funding from 3i Fund - marketscreener.com
Cerenome Launches New Corporate Identity As Integrated CNS Oncology Company | News - Voice of Alexandria
CNSY | Cerenome, Inc. Common Stock Stock Data, Price & News - Quiver Quantitative
Cerenome Reports Second Quarter 2026 Financial Results and Business Update - The Manila Times
What is the current Price Target and Forecast for Cerenome, Inc. (CNSY) - Zacks Investment Research
Cerenome, Inc. Stock (CNSY)Quote Nasdaq - marketscreener.com
CNSY Forecast — Price Target — Prediction for 2027 - TradingView
Cerenome (Nasdaq:CNSY)주식 분석 - simplywall.st
Cerenome (Nasdaq:CNSY)Stock Analysis - Simply Wall Street
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
CNSYCerenome Inc Stock Price and Quote - Finviz
Plus Therapeutics, Inc. will Change its Ticker to CNSY from PSTV - marketscreener.com
Cerenome will combine CNS cancer diagnostics, treatments and AI Aug. 3 - Stock Titan
Cerenome Launches as an Integrated CNS Oncology Company - GlobeNewswire
Cerenome Launches as an Integrated CNS Oncology Company - Yahoo Finance
Plus Therapeutics' CNSide Tests Influenced Treatment Decisions in 90% of Cases - Stock Titan
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV) - finance.yahoo.com
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY - Investing.com
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding - GlobeNewswire
Plus Therapeutics Reports First Quarter 2026 Financial - GlobeNewswire
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Plus Therapeutics taps ex-Kiora executive to help push CNS cancer pipeline - Stock Titan
To keep its Nasdaq listing, Plus Therapeutics enacts 1-for-25 split - Stock Titan
Plus Therapeutics Announces Reverse Stock Split - GlobeNewswire
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Plus Therapeutics Reports 2025 Results, Business Progress - GlobeNewswire
HIND Stock Price and Chart — NASDAQ:HIND - TradingView
LTRN Stock Price and Chart — NASDAQ:LTRN - tradingview.com
PLUS THERAPEUTICS (PSTV) Stock Price, News & Analysis - Stock Titan
EGRX Stock Price and Chart — OTC:EGRX - TradingView
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
Cerenome, Inc. Common Stock (CNSY) 財務データ
Cerenome, Inc. Common Stock (CNSY) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Cerenome, Inc. Common Stock (CNSY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Guse Kyle | Director |
Oct 01 '26 |
Option Exercise |
0.00 |
921 |
0 |
1,843 |
| Hawkins Richard J | Director |
Oct 01 '26 |
Option Exercise |
0.00 |
921 |
0 |
2,450 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
2,985 |
0 |
12,926 |
| Clowes Howard | Director |
Oct 01 '26 |
Option Exercise |
0.00 |
921 |
0 |
2,902 |
| HEDRICK MARC H | Chief Executive Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
16,439 |
0 |
60,922 |
| ANDREWS RONALD ASBURY | Director |
Oct 01 '26 |
Option Exercise |
0.00 |
921 |
0 |
1,843 |
| ANDREWS RONALD ASBURY | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
922 |
| van Es-Johansson An | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
922 |
| HEDRICK MARC H | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
0.00 |
16,439 |
0 |
44,483 |
| Clowes Howard | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
1,981 |
0.34%
大文字化:
|
ボリューム (24 時間):